| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* Immunology Department, Fundación Jiménez Díaz Capio, Madrid, Spain;
Pathology Department, Fundación Jiménez Díaz Capio, Madrid, Spain; and
Allergy Section and Experimental Medicine Unit, Gregorio Marañón Hospital, Madrid, Spain
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
Increasing evidence suggests that eosinophils are associated with development of lung dysfunction and subsequent immunopathological changes (5, 6, 7, 8, 9) through the release of lipid mediators, cytokines, cytotoxic proteins, and oxygen and nitrogen radicals (10, 11). Furthermore, evidence from animal models supports the view that eosinophils play an important role in tissue remodeling.
One key cytokine regulating the trafficking of eosinophils from bone marrow to the lung is IL-5, which regulates eosinophil proliferation, differentiation, and release from bone marrow (12, 13), and also acts in activation and tissue survival of eosinophils (14).
The specificity of IL-5 has also raised the possibility that blocking its activity might be a useful therapy for allergic diseases (15, 16). In this respect, several approaches have been made using monoclonal anti-IL-5 Abs, with varying results (17, 18, 19, 20, 21, 22, 23). Although these studies point to an important role for the eosinophil in asthma, the eosinophil hypothesis must nevertheless be tested more directly by attempting to generate eosinophil-focused therapies. Different experimental strategies have therefore been developed, such as GATA-1 knockout (KO) (24, 25) or CD49d and 
4
7 therapies for eosinophilic gastroenteritis (26), induction of eosinophils apoptosis by ligation of Siglec-8 (27), and anti-IgE therapy (28).
As a novel therapy, this paper evaluates the role of Galectin-3 (Gal-3) in a chronic asthma model. We previously reported that Gal-3 induces down-regulation of IL-5 gene expression (29, 30). Gal-3 is an IgE-binding protein which belongs to a family of proteins that bind -galactosides. It has a unique N-terminal domain, a highly conserved repetitive sequence rich in proline and glycine, and a globular C-terminal domain containing the carbohydrate recognition site. Gal-3 is expressed in a variety of tissues and cell types (31). In addition, it has been implicated in different processes, including inflammation and allergic pathologies (32, 33), and the effect on the IL-5 gene raises interesting possibilities in the regulation of allergic reactions (29, 30). In a previous work, intratracheal instillation of plasmid-Gal-3 in acute sensitized rats that had been Ag-challenged by inhalation was shown to lead to an improvement, in terms of both cellular inflammatory infiltrate and pulmonary function (34). We therefore wanted to ascertain whether these beneficial effects would also apply to a chronic model.
Accordingly, this study sought to assess the efficacy of delivery of therapeutic Gal-3 by gene therapy in a well-characterized mouse model of chronic airway inflammation, hyperresponsiveness, and remodeling.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
All experimental procedures conformed to international standards of animal welfare and were approved by the Fundación Jiménez Díaz animal committee. Male A/J mice (specific pathogen free; 5 wk old) were purchased from Harlan Iberica.
Induction of chronic asthma by intranasal administration of OVA and Gal-3 gene treatment
Mice were placed in a small box and anesthetized with inhaled Forane. Anesthetized mice were instilled with 1 mg/ml OVA (grade V; Sigma-Aldrich) intranasally. Administration of OVA was performed 3 days/week for 12 wk, using a previously described method (35).
To analyze the minimal dose of plasmid-Gal-3 that induced IL-5 inhibition, we tested several doses ranging from 25 to 100 µg of DNA. Whereas 25 µg had no effect, 50 µg proved to be the minimal dose that brought about complete IL-5 gene inhibition. Above 100 µg, a plateau was reached (data not shown). Fourteen days after the first OVA instillation and once every 15 days thereafter, mice were treated by intranasal instillation with 50 µl of plasmid (1 mg/ml) encoding Gal-3 (pEGFP-Gal-3, n = 39) or with plasmid without insert (pEGFP, n = 20) or with saline instead of plasmid instillation (OVA, n = 35) as positive controls. An additional negative control group was used in which mice were injected with saline and exposed to saline inhalation (SS, n = 20).
Plasmid DNA preparation
The human Gal-3 gene (BlueScript SK-GAL-3 furnished by Dr. F. T. Liu, La Jolla Institute for Allergy and Immunology, San Diego, CA) was cloned into an eukaryotic expression vector pEGFP plasmid (BD Clontech). pDNA was purified using the Wizard DNA purification system (Promega) and stored at –20°C in pyrogen-free saline.
Bronchoalveolar lavage (BAL), cell analysis, and RNA preparation
Twenty-four hours after the last administration of Ag, the mice were anesthetized and the lungs lavaged three times with sterile 0.5 ml of PBS. Cells obtained were counted and used for RNA extraction and for cytometric analysis (34). Total RNA was isolated from lungs by TRIzol Reagent (Invitrogen Life Technologies) and was treated with DNase I (Promega). RNA was measured by spectrophotometry, and 1 µg of RNA was used for first-strand cDNA synthesis with the SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen Life Technologies).
Gal-3 detection
Immunohistochemistry was performed with the paraffin-embedded sections. The endogenous peroxidase activity as well as nonspecific protein binding was sequentially blocked using 0.3% hydrogen peroxide and 5% normal goat serum, respectively. The sections were incubated with affinity purified rabbit anti-Gal-3 Ab (BD Biosciences), or normal rabbit IgG Ab (control) at 10 µg/ml for 30 min at room temperature and were then washed five times in PBS. Bound Ab was detected by sequential incubation with biotinylated goat anti-rabbit Ab and streptavidin-HRP followed by 3,3-diaminobenzidine (DakoCytomation). Slides were then washed in water and counterstained with hematoxylin Gill no. 2 (Sigma-Aldrich).
Cytokine expression in lung tissues by real-time quantitative PCR
Quantitative real-time PCR was performed on a 7500 Real-time PCR System (Applied Biosystems). TaqMan PCR was performed using a 20-µl final reaction volume containing 10 µl of TaqMan Universal PCR Master Mix (Applied Biosystems), 1 µl of 20x Assays-on-Demand Gene Expression Assay Mix, and 9 µl of cDNA diluted in RNase-free water. Each assay was performed in triplicate. The PCR conditions used in all reactions were: 2 min at 50°C, 10 min at 95°C, with 40 two-step cycles (95°C for 15 s and 60°C for 60 s). Assays-on-Demand Gene Expression primers to IL-4, IL-5, IL-13, IL-10, and rRNA (used as Endogen) were obtained from Applied Biosystems (
www.appliedbiosystems.com/
).
Determination of total serum IgE and OVA-specific IgG1 and IgE
Total serum IgE and OVA-specific IgE were measured using an ELISA kit. OVA-specific IgG1 was determined by ELISA using a biotin anti-mouse IgG1 (BD Biosciences/BD Pharmingen).
Measurement of collagen
The amount of pulmonary fibrosis was determined by measuring total pepsin-soluble lung collagen, using the Sircol Collagen Assay kit (Biocolor) as described previously (36).
Determination of airway responsiveness to methacholine
Mice airway responsiveness was assessed every 15 days until 12 wk. Four individual whole body plethysmograph chambers, obtained from Buxco, were used as described elsewhere (37).
Tissue processing and histological analysis
Right lungs were taken from mice under terminal anesthesia, inflated with 10% formalin, and immersed in the same solution before tissue processing in paraffin-embedded blocks. Five-micrometer sections were stained with H&E to evaluate general morphology. Mucus-secreting goblet cells were visualized on periodic acid-Schiff (PAS), and Masson Trichrome stain was used for assessment of subepithelial fibrosis. Analyses were performed in a blind fashion, and slides were presented in random order for each examination.
The results were analyzed, in blind conditions, using an arbitrary intensity scale: 0, no cellular inflammatory infiltrate, or basal extracellular matrix (ECM) staining or no staining; 1, mild cellular inflammatory infiltrate or mild staining; 2, moderate cellular inflammatory infiltrate or moderate staining; 3, severe cellular inflammatory infiltrate or intense staining) using H&E, Masson, and PAS, respectively. Semiquantification was done in the animals studied: pEGFP-Gal-3, n = 39; OVA, n = 35; pEGFP, n = 20; SS, n = 20.
Statistical analysis
Results were expressed as mean ± SD with a group size of 20–40 from three different experiments. Variance analysis was used for statistical comparisons between groups, followed by the Tukey test (where applicable) using GraphPad Prism 4 Software. Statistical significance was set at p < 0.05.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
After instillation of 50 µg of plasmid into the lungs, Gal-3 was detected by immunohistochemistry. As shown in Fig. 1, immunohistochemical analysis of Gal-3 expression showed an increase in staining (brown color) in the lungs of mice treated with plasmid-encoding Gal-3 (Fig. 1C) compared with the normal lungs (Fig. 1A) and with inflamed lungs (Fig. 1B). In lungs treated with gene therapy, Gal- 3 was expressed mainly in peribronchial epithelial cells. Staining was not observed when normal rabbit IgG was used instead of rabbit anti-Gal-3 Ab (Fig. 1D). These results indicated that mice receiving the Gal-3 gene overexpressed Gal-3 protein.
|
Activated T cells migrate to the lungs and release inflammatory cytokines to orchestrate the allergic response. We therefore assessed the effect of Gal-3 gene therapy on lung cytokine levels after 12 wk of chronic OVA challenge in a situation similar to chronic asthma. The results indicated that IL-5, IL-4, IL-10, and IL-13 levels were increased with respect to negative controls treated with saline instead of Ag (p < 0.05; Fig. 2). When mice were treated during 12 wk with Ag and pEGFP-Gal-3, the relative level of IL-5 expression was significantly lower than it was among OVA-exposed mice without gene treatment: 0.45 vs 0.86, p < 0.01, representing close to 75.2% inhibition (Fig. 2A). However, treatment with empty plasmid does not significantly modify the IL-5 expression comparing with the OVA group. Also, there were statistically significant differences comparing groups treated with empty plasmid and with plasmid encoding for Gal-3: 0.76 vs 0.45, p < 0.01.
|
BAL and peripheral blood eosinophils
The percentage of eosinophils in BAL and peripheral blood was examined by flow cytometry. As shown in Table I, there was a strong and persistent eosinophilic inflammation in mice in the OVA group in the 12th week (chronic stage) after sequentially repeated OVA administration. pEGFP-Gal-3 treatment significantly reduced the numbers of total cells and eosinophils, in both BAL fluid and peripheral blood (Table I). The BAL eosinophil count was 4.38 ± 1.05% for treated (pEGFP-Gal 3, n = 39) vs 11.09 ± 2.4 for untreated (OVA, n = 35) animals (p < 0.01). The treatment with empty plasmid do not apparently modify eosinophil count in asthmatic mice (9.8 ± 2.6, n = 20). In peripheral blood, the reduction obtained was significant, albeit to a lesser extent than that obtained in BAL fluid (BALF).
|
Determination of total serum IgE and OVA-specific IgG1 and IgE
We wished to ascertain whether treatment with plasmid-encoding Gal-3 might alter total and specific IgE levels. OVA-sensitized mice had high levels of total and specific serum IgE. As can be seen in Table II, there were no detectable changes in IgE from mice treated with plasmid with Gal-3 and OVA and pEGFP groups. Data shown in Table II indicate that Gal-3 does not interfere with total or with specific IgE synthesis. Determination of specific IgG1 against OVA showed that the response against the Ag was not modified in treated mice.
|
To quantify collagen deposition in the lung, the Sircol collagen assay was used. Collagen content of each airway preparation was normalized to the weight of the lung in each group, to correct for differences in the yield of airway dissection. As shown in Fig. 3, the group of mice treated with plasmid-encoding Gal-3 gene had significantly lower levels of measurable collagen than in the OVA group (8.49 ± 3 against 42.96 ± 12 µg of total collagen/100 mg of lung, p < 0.001) reaching normal levels similar to those registered for the saline group (9.2 ± 2.7).
|
Airway hyperresponsiveness
Airway function was assessed using whole body plethysmography. Enhanced pause, a calculated value that correlates with measurement of airway resistance, was performed at 12 wk in chronically OVA-exposed mice. Allergen-treated mice developed a significantly enhanced response to methacholine when compared with saline-treated animals (SS) after 12 wk (Fig. 4). As expected, Gal-3-treated mice displayed a decreased response to methacholine compared with OVA asthmatic controls at 4 wk with significance being reached at methacholine concentrations of 48 mg/ml (data not shown).
|
Histopathologic examination
Chronic allergen challenge resulted in increased inflammatory infiltrates in perivascular and peribronchial regions, consisting mainly of eosinophils (Fig. 5B). In contrast, in plasmid-encoding Gal-3-treated mice (Fig. 5D), inflammatory cell infiltrates were absent, with a pattern similar to that of control mice (saline group, Fig. 5A). Fig. 5C shows that after sensitization and airway challenge with OVA and instillation with empty plasmid, the infiltrate is similar to that obtained in the OVA group. Increased subepithelial deposition of ECM proteins, specifically collagen, is a prominent feature of airway remodeling. We examined connective tissue in lung sections stained with Masson Trichrome. Saline control mice showed a thin uniform layer of matrix in peribronchiolar supepithelial regions (Fig. 5E), whereas chronic Ag challenge was associated with an increase in matrix in the subepithelial layer of the airways and in perivascular regions, as shown by a dramatic increase in both the extent of collagen deposition and intensity of staining (Fig. 5F), also found in the pEGFP empty plasmid group (Fig. 5G). In marked contrast, matrix deposition in these same regions was consistently abrogated in Gal-3-treated mice (Fig. 5H).
|
Semiquantitative analysis of stains from the groups of mice revealed that inflammatory cell infiltrates, subepithelial deposition of collagen, and mucus secretion from goblet cells were significantly different between pEGFP-Gal-3 and OVA and pEGFP mice. In contrast, the grading of inflammation and stain were similar between pEGFP-Gal-3 and SS groups (Table III).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
Gal-3 belongs to a family of soluble proteins with affinity for -galactose-containing oligosaccharides. In previous in vitro studies, we demonstrated that Gal-3 down-regulates IL-5 gene expression in different cell types, such as Ag-specific T cell lines, human eosinophils, and PBMC from allergic patients (29, 30). The IL-5 down-regulation observed in these cells is specifically due to Gal-3, because this effect is reversed when specific anti-Gal-3 Abs are used (29). Subsequent in vivo studies at our laboratory have shown that intratracheal instillation of plasmid-encoding Gal-3 in acute asthmatic rats leads to improvement in the cellular inflammatory infiltrate and pulmonary function (34).
Human asthma, however, is a chronic disease, with structural changes leading to airway remodeling (38, 39, 40). We therefore investigated the possibility of extending our acute rat model to a chronic asthma situation, so as to study the effect of Gal-3 gene therapy and its influence on the remodeling process.
Recently, innovative protocols have been published which involve chronic inhalation of OVA (35, 41) in a murine chronic asthma model. This model has the additional advantage of relying on natural immunization (without the use of adjuvant), which is more like the situation experienced by asthmatic patients. These studies also demonstrated that there is a strain-specific response similar to genetic restrictions observed in humans. A/J mice are more prone to develop the chronic model with the characteristics of remodeling.
Using this experimental model, we have shown that down-regulation of the IL-5 gene in the lung, through nasal instillation of plasmid-encoding Gal-3, brings about a reduction in the eosinophil count in BAL and peripheral blood, and is associated with a significant decrease in bronchial hyperreactivity, ECM protein expression in the airway and mucus, and collagen accumulation in the airways. These data support the role of eosinophils in these processes and suggest a link between eosinophilic infiltration and airway remodeling, as reported elsewhere (25, 42, 43). We contend that IL-5 down-regulation reduces the number of eosinophils in BAL, pulmonary tissues, and peripheral blood, and that this, in turn, leads to a reduction in eosinophilic inflammation during the acute period and a clear improvement in chronicity and remodeling.
IL-5 is one of the main regulatory cytokines that modulates eosinophils, the major inflammatory effector cells in allergic disorders (44, 45). Furthermore, IL-5 plays an important role in airway remodeling observed in experimental asthma (46). These characteristics make IL-5 an excellent target for treatment of eosinophilic airway inflammation. The role of IL-5 in eosinophil biology has been extensively studied, though the precise mechanisms that enhance eosinophilopoiesis in bone marrow of asthmatics remain to be fully elucidated. Inhalation of allergen is known to increase the number of IL-5-responsive eosinophil progenitors in bone marrow (47). In vivo animal models indicate that IL-5 production restricted to the airways is insufficient to explain this phenomenon, and that systemic IL-5 is implicated (48). There have been several recent attempts to dissect the role of the eosinophil in asthma by using humanized mAbs against IL-5, with variable results (17, 18). Despite the fact that anti-IL-5 almost totally ablated eosinophils in the blood and sputum (17), tissue eosinophils were nevertheless reduced rather than depleted (18), possibly as a result of down-regulated IL-5R expression of airway eosinophils (49).
In our chronic experimental model, the use of Gal-3 gene therapy led to a 72–92% inhibition in airway and blood eosinophils in 12-wk-treated mice. Gene therapy has some advantages over conventional pharmacologic treatments. It avoids parenteral administration with its possible adverse effects. Delivery of therapeutic proteins by gene therapy has the additional advantage of enhancing the efficacy, convenience, and cost-effectiveness of chronic disease treatment (50). It has been shown that direct gene transfer results in rapid DNA uptake and that 1–3 days after administration, genes express a biologically active protein in lung (51), which remains there for as long as 28 days (52).
As pointed out, AHR is not dependent on IgE production in this model, a finding consistent with the report that allergic AHR develops normally in IgE-deficient mice (53). The marked improvement in airway hyperreactivity in Gal-3-treated mice plus the inhibition of airway remodeling (measured as diminished expression of ECM proteins in the airways and mucus accumulation) are in line with other published data, which postulate a new role for eosinophils and suggest a link between eosinophilic infiltration and airway remodeling (9, 42, 43, 46). Pulmonary function analysis thus shows that Gal-3 treatment brought about a marked inhibition in AHR.
Eosinophils produce fibrogenic factors and induce fibroblast proliferation. There is increasing evidence to show that eosinophils may be important in the pathophysiology of airway remodeling (54, 8). Our data suggest that Gal-3-induced eosinophil depletion leads to inhibition of airway alteration (or remodeling, as it is known) i.e., cellular infiltration, goblet cell hyperplasia, subepithelial fibrosis, etc. In the gene therapy treated mice, histologic analysis of the airways after chronic allergen challenge showed that there were fewer or no perialveolar and peribronchial cellular infiltrates and that the structure of the airway epithelium was conserved. In light of these results, Gal-3 therapy might be thought useful for the purpose of preventing airway remodeling.
We also tested variations in other cytokines, such as IL-4, IL-10, and IL-13, which are important in allergic reactions. IL-10 is a pleiotropic cytokine released from various cells, including T cells. The role of IL-10 in asthma remains controversial: whereas some studies report IL-10 expression to be higher in subjects with asthma than in control subjects (55, 56), others report lower IL-10 levels (57, 58). We observed an increase in IL-10 levels in the lungs of nontreated asthmatic mice. High IL-10 levels in the OVA group of mice suggest that IL-10 may serve as an endogenous feedback, an inhibitory mechanism to modulate the inflammatory response.
With respect to the results yielded for other cytokines, such as IL-4 and IL-13, no significant changes were found as a result of the treatment. These data confirm our previous studies, in which Gal-3 was observed to specifically inhibit IL-5 transcription, with no collateral effects on other cytokines. The explanation for this may lie in the finding that IL genes are differentially regulated (59, 60).
In contrast with our results, a recent paper has demonstrated in a model of OVA-induced asthma, that Gal-3-deficient mice developed fewer eosinophils than did positive control asthmatic mice (61). Several differences may have contributed to this divergence. In the first place, the mice in our experiment received the Gal-3 gene by nasal instillation directly into the bronchial tree, with the ensuing increase in this protein in the respiratory tract, which is precisely the site where the inflammatory reaction takes place. Second, the strain used in the above experiment is not as prone to asthmatic allergic reaction as the A/J mouse (35), and finally, and most remarkably, is the consideration that the effects of exogenously administered substances (either by using a recombinant protein or a gene delivery vector) are not necessarily the same as the endogenous ones as has been widely documented (62, 63). Furthermore, we have demonstrated that in mice treated with gene therapy, there is an induction of this protein in peribronchial epithelial cells when compared with lungs of normal noninduced mice.
Interestingly, the inhibitory effects of Gal-3 on the inflammatory cytokines and chemokines in guinea pig asthma models with special mention to selective inhibition of IL-5 gene transcription have been recently reported (64).
The beneficial effect of Gal-3-gene therapy is due to IL-5 down-regulation and the ensuing improvement in eosinophilic inflammation. The possibility of another complementary effect induced by DNA itself, in a manner akin to that reported for DNA vaccination (65, 66), has been ruled out, because experiments conducted using plasmid without insert failed to interfere with the asthmatic inflammation.
Interventions that regulate Th2 cytokine effector pathways are attractive as potential therapeutic targets, and we assume that concomitant treatment throughout the period of chronic allergen exposure might result in abrogation of Th2 immune-mediated airway inflammation, with subsequent attenuation of aspects of airway remodeling and AHR.
Our results thus confirm that, through inhibition of IL-5 gene transcription, Gal-3 gene treatment in experimental chronic asthma leads not only to the abrogation of acute asthma, but also, most importantly, to an improvement in chronic airway inflammation and changes in the remodeling process.
|
Disclosures |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
|
Footnotes |
|---|
1 This work was supported by Spain Health Research Fund Grants FIS 01/3019 and Red RESPIRA C03/011 (Fondo de Investigaciones Sanitarias (FIS)); Ministry of Education and Science Grant SAF 2003-09443; and fellowship grants from the Conchita Rábago Foundation (to B.S. and E.Ll.) and the FIS (E.Ló. and E.C.). 
2 Address correspondence and reprint requests to Dr. Victoria del Pozo, Immunology Department, Fundación Jiménez Díaz, Avenida Reyes Catolicos 2, 28040 Madrid, Spain. E-mail address: vpozo{at}fjd.es
3 Abbreviations used in this paper: AHR, airway hyperresponsiveness; Gal-3, Galectin-3; BAL, bronchoalveolar lavage; BALF, BAL fluid; PAS, periodic acid-Schiff; ECM, extracellular matrix.
Received for publication April 20, 2005. Accepted for publication November 22, 2005.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
RII induces down-regulation of IL-5 gene: implication of the promote sequence IL-5 RE III. Glycobiology 10: 237-242. on human eosinophils. II. IL-5 down-modulates its receptor via a proteinase-mediated process. J. Immunol. 169: 6459-6466. gene transfer inhibits pulmonary allergic responses in mice. J. Immunol. 157: 3216-3219. [Abstract] on immunoglobulin E, cellular infiltration and airway responsiveness in a murine model of allergic asthma. Am. J. Respir. Cell Mol. Biol. 19: 826-835. This article has been cited by other articles:
|
|
 |
|
  L. V Norling, M. Perretti, and D. Cooper Endogenous galectins and the control of the host inflammatory response J. Endocrinol., May 1, 2009; 201(2): 169 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Saegusa, D. K. Hsu, H.-Y. Chen, L. Yu, A. Fermin, M. A. Fung, and F.-T. Liu Galectin-3 Is Critical for the Development of the Allergic Inflammatory Response in a Mouse Model of Atopic Dermatitis Am. J. Pathol., March 1, 2009; 174(3): 922 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bi, L. A. Earl, L. Jacobs, and L. G. Baum Structural Features of Galectin-9 and Galectin-1 That Determine Distinct T Cell Death Pathways J. Biol. Chem., May 2, 2008; 283(18): 12248 - 12258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. MacKinnon, S. L. Farnworth, P. S. Hodkinson, N. C. Henderson, K. M. Atkinson, H. Leffler, U. J. Nilsson, C. Haslett, S. J. Forbes, and T. Sethi Regulation of Alternative Macrophage Activation by Galectin-3 J. Immunol., February 15, 2008; 180(4): 2650 - 2658. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Breuilh, F. Vanhoutte, J. Fontaine, C. M. W. van Stijn, I. Tillie-Leblond, M. Capron, C. Faveeuw, T. Jouault, I. van Die, P. Gosset, et al. Galectin-3 Modulates Immune and Inflammatory Responses during Helminthic Infection: Impact of Galectin-3 Deficiency on the Functions of Dendritic Cells Infect. Immun., November 1, 2007; 75(11): 5148 - 5157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Pilette, B. Colinet, R. Kiss, S. Andre, H. Kaltner, H-J. Gabius, M. Delos, J-P. Vaerman, M. Decramer, and Y. Sibille Increased galectin-3 expression and intra-epithelial neutrophils in small airways in severe COPD Eur. Respir. J., May 1, 2007; 29(5): 914 - 922. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
, OVA group (n = 35); 
, pEGFP group (n = 20); 
, pEGFP-Gal-3 group (n = 39); and 
, SS group (n = 20). Significant differences in IL-5 (**, p < 0.01) and IL-10 (*, p < 0.05) expression levels were obtained for pEGFP-Gal-3 vs OVA and pEGFP groups. In the case of empty plasmid, no significant differences were found compared with the OVA group.
0.05 and ***, p 